Roger Jeffs Sells 35,249 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 35,249 shares of the stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $2,520,655.99. Following the completion of the transaction, the chief executive officer owned 1,130,426 shares of the company’s stock, valued at $80,836,763.26. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Roger Jeffs also recently made the following trade(s):

• On Wednesday, May 27th, Roger Jeffs sold 6,428 shares of Liquidia stock. The stock was sold at an average price of $62.18, for a total value of $399,693.04.
• On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $60.38, for a total transaction of $1,509,500.00.
• On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total transaction of $1,528,250.00.
• On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $58.65, for a total transaction of $1,466,250.00.
• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total transaction of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $56.29, for a total transaction of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.

Liquidia Stock Up 1.6%

Shares of LQDA opened at $77.75 on Thursday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock has a market capitalization of $6.91 billion, a PE ratio of 555.40 and a beta of 0.55. The company’s 50-day simple moving average is $67.08 and its 200-day simple moving average is $47.81. Liquidia Corporation has a 1 year low of $14.04 and a 1 year high of $82.96.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s revenue for the quarter was up 4187.1% on a year-over-year basis. Analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB purchased a new position in Liquidia in the second quarter valued at approximately $1,993,000. Fulcrum Equity Management purchased a new stake in shares of Liquidia during the 2nd quarter worth approximately $399,000. Fluent Financial LLC purchased a new stake in shares of Liquidia during the 2nd quarter worth approximately $287,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at $1,395,000. Finally, Seven Fleet Capital Management LP grew its position in shares of Liquidia by 124.5% in the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after buying an additional 113,609 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s YUTREPIA patent case appears to be turning more favorable, and the company is also being highlighted for expanding its patent position around the drug. That improves the outlook for protecting its pulmonary hypertension franchise and supports the bullish case for the stock. Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
• Neutral Sentiment: Brokerage coverage remains constructive overall, with Liquidia receiving a consensus “Moderate Buy” rating from analysts. That supports the stock’s longer-term outlook, but it is not a new catalyst on its own. Liquidia Corporation (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: Several insiders, including the CEO, CFO, general counsel, CAO, and others, disclosed stock sales at about the same price level. The trades were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, but the size and number of sales may still raise some investor caution. SEC filing – Roger Jeffs sale

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LQDA shares. BTIG Research increased their price target on Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Needham & Company LLC boosted their price objective on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Bank of America restated a “neutral” rating and set a $79.00 target price (up from $64.00) on shares of Liquidia in a research note on Monday, June 29th. Oppenheimer set a $75.00 target price on shares of Liquidia in a report on Friday, June 5th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).